clozapine monitoring
Mandatory laboratory surveillance program required for patients taking clozapine to detect potentially fatal blood disorders, primarily agranulocytosis.
Full Definition
Clozapine monitoring refers to the comprehensive laboratory surveillance system required for all patients receiving clozapine therapy due to the medication's risk of causing potentially fatal blood disorders, particularly agranulocytosis. The monitoring protocol includes complete blood count with differential before treatment initiation, weekly for the first six months, biweekly for the next six months, and monthly thereafter. Absolute neutrophil count (ANC) and white blood cell count (WBC) are the critical parameters monitored. Specific thresholds trigger intervention: ANC below 1500/μL or WBC below 3500/μL requires immediate discontinuation. This monitoring is typically coordinated through national registries that track prescribing and laboratory results. The rigorous monitoring requirement reflects clozapine's unique efficacy in treatment-resistant schizophrenia balanced against its serious safety risks. Additional monitoring may include metabolic parameters and clozapine plasma levels.
Usage
Usage note: Often abbreviated as CPMS (Clozapine Patient Monitoring Service) in some regions; specify local monitoring system when relevant.
In Context
- "The psychiatrist emphasized the importance of strict adherence to clozapine monitoring requirements." — Patient education document
- "Clozapine monitoring detected a concerning drop in the patient's neutrophil count at week 8." — Laboratory alert notification